Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization: real-world data from Mexico


  • Guillain-Barré syndrome (GBS) is extremely infrequent among recipients of all vaccines against severe acute respiratory coronavirus 2 (SARS-CoV-2), the risk is outweighed by the protection provided by these vaccines.

Why this matters

  • The epidemiology of adverse events following immunization against SARS-CoV-2, including GBS, remains incompletely understood, particularly in underdeveloped countries and underserved regions.

  • Clinicians are now equipped with more in-depth knowledge of the benefit-risk ratio of SARS-CoV-2 immunization, with regards to GBS as a potential adverse event.